drugset
drugset / Trial / NCT03025022

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

NCT03025022 ↗

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelOther

Summary

The objective of this study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of 14C-JNJ-42847922 in healthy subjects after a single oral dose of 40 milligram (mg) 14C-JNJ-42847922 containing maximally 100 MicroCurie. Safety and tolerability will also be assessed.

Timeline

Start
2017-01-17
Primary completion
2017-02-27
Completion
2017-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule 40 mg Oral

Indications

No indication recorded.